Technical Analysis for INFI - Infinity Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 3.04 -4.40% -0.14
INFI closed down 4.4 percent on Friday, February 26, 2021, on 66 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Mar 1
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical INFI trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -4.40%
Oversold Stochastic Weakness -4.40%
Narrow Range Bar Range Contraction -10.85%
NR7 Range Contraction -10.85%
Wide Bands Range Expansion -10.85%
Oversold Stochastic Weakness -10.85%
1,2,3 Pullback Bullish Bullish Swing Setup -10.59%
Older End-of-Day Signals for INFI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Support 1 day ago
Down 5% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Infinity Pharmaceuticals, Inc. Description

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company is pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. IPI-145 is in an ongoing Phase I dose-escalation trial in patients with advanced hematologic malignancies and in a Phase IIa study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase II signal-finding study in patients with rheumatoid arthritis. IPI-443 is undergoing preclinical studies to enable Phase I development. Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) and in an exploratory Phase Ib/II trial in combination with everolimus in NSCLC patients with a KRAS mutation. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Diseases Acid Drug Discovery Inflammation Chemical Substances Small Cell Lung Cancer Non Small Cell Lung Cancer Rheumatoid Arthritis Asthma Mild Hematologic Malignancies Fatty Acid Nsclc Phosphoinositide 3 Kinase Inhibitor Docetaxel Kras Pyrimidines Allergic Asthma Purines

Is INFI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 5.98
52 Week Low 0.6
Average Volume 3,936,470
200-Day Moving Average 1.67
50-Day Moving Average 3.13
20-Day Moving Average 3.81
10-Day Moving Average 3.63
Average True Range 0.48
ADX 35.4
+DI 27.08
-DI 24.16
Chandelier Exit (Long, 3 ATRs ) 4.54
Chandelier Exit (Short, 3 ATRs ) 4.37
Upper Bollinger Band 4.79
Lower Bollinger Band 2.83
Percent B (%b) 0.11
BandWidth 51.46
MACD Line 0.01
MACD Signal Line 0.18
MACD Histogram -0.169
Fundamentals Value
Market Cap 195.19 Million
Num Shares 64.2 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -9.05
Price-to-Sales 74.85
Price-to-Book 8.03
PEG Ratio -0.05
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.54
Resistance 3 (R3) 3.56 3.41 3.46
Resistance 2 (R2) 3.41 3.28 3.40 3.43
Resistance 1 (R1) 3.22 3.20 3.15 3.21 3.40
Pivot Point 3.08 3.08 3.04 3.07 3.08
Support 1 (S1) 2.89 2.95 2.82 2.87 2.68
Support 2 (S2) 2.74 2.87 2.73 2.65
Support 3 (S3) 2.56 2.74 2.62
Support 4 (S4) 2.54